Theolytics is a clinical stage company, developing a new generation of oncolytic viruses for intravenous administration. The ability to specifically target tumour cells and the tumour micro-environment may potentially bring practice changing therapies to patients with hard-to-treat cancers such as platinum-resistant ovarian cancer and colorectal cancer.
Sound Contact: Johan Kordel (Board Director)
Read an interview with CEO, Dave Apelian: Maximizing value when developing oncolytic viral therapy
